Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or >5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study
Gastroenterol Hepatol (N Y)
.
2024 Dec;20(12 Suppl 11):8-9.
PMID:
39896969
PMCID:
PMC11784562
No abstract available